In a study using a novel mouse model, researchers found that SARS-CoV-2 infection in severe asthma, particularly the eosinophilic allergic subtype, led to increased inflammation and worsened COVID-19 outcomes. The study revealed heightened infiltration of inflammatory cells, elevated cytokines linked to severe asthma, and activation of the NLRP3 inflammasome in the lungs of mice with pre-existing asthma. The findings suggest a potential target for early treatment in severe asthma cases associated with a dysregulated innate immune response during COVID-19.